This page shows the latest FasT CAR-T news and features for those working in and with pharma, biotech and healthcare.
The company's 'FasT CAR-T' only requires eight days to complete the production process, which is made up of the one day of manufacturing plus seven days for releasing tests, ... Without support from patients, their families, and clinical scientists, we
EMA fast-track could help Janssen close gap. Janssen has been granted a valuable PRIME (Priority Medicines) designation from the European Medicines Agency for its CAR-T candidate for multiple myeloma, ... The CAR-T therapy would complement Janssen's
NHS England claims adult leukaemia access is first in Europe. NHS England has agreed a market access deal with Gilead for its groundbreaking CAR-T therapy Yescarta, and is claiming it ... It is likely that we are only beginning to see the benefits that
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Rather than a contained project or platform, its contribution to CAR-T is through a contract manufacturing development organisation. ... Collaborating with pharma companies, Oxford Biomedica uses its infrastructure to produce other companies’ licensed
Most notably, fast patient access for CAR-T cell therapies, Gilead’s Yescarta and Novartis’ Kymriah, where England has been ahead of its European counterparts in making the drugs available. ... CAR-T therapies are cost-effective for these patients,
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...